NEXLIZET (bempedoic acid and ezetimibe)
Heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering
Key Facts
About Esperion Therapeutics
Esperion Therapeutics is dedicated to improving cardiovascular health by providing convenient, oral therapies that lower LDL-cholesterol (LDL-C) for patients who cannot achieve their treatment goals with statins alone. The company achieved a major milestone with the U.S. FDA approval and commercial launch of NEXLETOL and NEXLIZET in 2020, supported by a robust outcomes trial (CLEAR Outcomes) demonstrating cardiovascular risk reduction. Its strategy focuses on expanding global market access, driving commercial adoption, and leveraging its bempedoic acid platform to potentially address other cardiometabolic conditions.
View full company profileTherapeutic Areas
Other Heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering Drugs
| Drug | Company | Phase |
|---|---|---|
| NEXLETOL (bempedoic acid) | Esperion Therapeutics | Approved |